WINDSOR, Conn., Feb. 27, 2018 -- Scapa Healthcare, a trusted strategic outsource partner of skin-friendly, turnkey solutions, unveiled its three R&D Centers of Excellence. Each Center offers full turn-key development services, extensive design and engineering expertise and state-of-the-art manufacturing technologies to help customers bring innovative products to market rapidly.
Located in Knoxville, TN, Orangeburg, NY and Ramsbury, UK, Scapa Healthcare’s R&D Centers of Excellence have proven capabilities delivering full turnkey solutions. Each Center features state-of-the-art manufacturing capabilities, R&D labs, specialized engineers, scientists and program managers to drive each program from development to manufacturing to commercialization in an efficient, controlled and expedited manner.
The programs are managed through a structured, lean and effective product lifecycle management process, ensuring that all products delivered to market are under full compliance. The Product Development team works jointly with the customer throughout the entire process; from product design and materials selection, to prototyping and user studies, and finally to product validation, manufacturing and commercialization. Beyond product development, Scapa Healthcare can assist with regulatory services including building technical files, stability studies, sterilization validation, product registration and post-market surveillance.
“We recognize that speed to market is critical in our industry, so we have made significant investments in technology, capabilities and personnel to help our customers bring products rapidly into the global healthcare market,” said Mike Muchin, VP of Product Development at Scapa Healthcare. “Seamlessly working side by side with our customers, even those with manufacturing capabilities, we ensure that their products are collaboratively developed and commercialized quickly and efficiently. By leveraging our development and manufacturing expertise, they can focus their efforts on marketing and commercialization of their products.”
Every R&D Center has a Class 7 or Class 8 cleanroom, robust quality systems and is compliant with ISO and FDA registrations for medical device manufacturing facilities.
About Scapa Healthcare
Scapa Healthcare is a global trusted strategic outsource partner of skin friendly turn-key solutions for advanced wound care, consumer wellness and medical device markets. Scapa Healthcare partners with market leaders to design, develop, manufacture and commercialize innovative skin contact solutions to meet end-user needs. Scapa Healthcare offers turn-key development services, including design and project management; coating; converting, perforation and assembly; printing and packaging; and sterilization services. For more information, visit: www.scapahealthcare.com
Media Contact
Jordan Bouclin
SVM Public Relations and Marketing Communications
[email protected]
(401)490-9700
Scapa Healthcare Contact
Beth Schivley
SHC MarCom Manager
[email protected]
860-902-8157


Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Anta Sports Expands Global Footprint With Strategic Puma Stake
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 



